|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that MMP2 promoter polymorphisms may provide some predictive value for HCC recurrence after LT.
|
18177474 |
2008 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Our results reveal that BA exerts its anti-metastatic effect against DEN-induced hepatocellular carcinoma by inhibiting the activities and expressions of MMP-2 and MMP-9.
|
20084675 |
2010 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma.
|
21712445 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that phorbol-12-myristate-13-acetate (PMA)-stimulated invasion of the hepatocellular carcinoma (HCC) SNU-387 and SNU-398 cells and that PMA induced the secretion of MMP-9 in the cells, but did not induce the secretion of MMP-2.
|
12745093 |
2003 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MMP2 mRNA levels were increased in 19% of HCCs, whereas MMP2 mRNA was not detectable in HCC cell lines, suggesting that MMP2 was derived only from tumour stroma cells.
|
15455231 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To elucidate biological characteristics of HCCs expressing CD133, we evaluated migration assay and the mRNA expression levels of CD133, invasion-associated genes [urokinase plasminogen activator receptor (uPAR), villin 2 (VIL2), and MMP1 and MMP2], and EMT regulators (Snail, Slug, Twist, E-cadherin, and N-cadherin) by real-time PCR in HCC cell lines including HepG2, Hep3B, Huh7, PLC/RFP/6, SNU423, SNU449, and SNU475.
|
20969862 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In an orthotopic model of HCC in nude mice, P-5m treatment effectively reduced the lung metastasis as well as the expression of MMP-2 in the tumor tissues.
|
22395332 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we are going to determine whether GRP78 knockdown affect the ECM degradation and the role of MMP-2 and MMP-9 in these process in hepatocellular carcinoma cells.
|
22546345 |
2012 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results suggest that down-regulation of Gli-1 suppresses HCC cell migration and invasion likely through inhibiting expressions and activations of MMP-2, 9 and blocking EMT.
|
24792036 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The cases which were negative for ALCAM expression had shorter time to recurrence than positive cases, and univariate and multivariate survival analyses showed that ALCAM was an independent risk factor of HCC recurrence. qRT-PCR and Western blotting showed that the expression of EMT related genes (MMP-2, MMP-9, E-caherin and vimentin) significantly changed as a result of interfering or overexpression of ALCAM, and ALCAM was significantly associated with EMT in HCC.
|
29375378 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report, we present clinical data obtained from HCC patients indicating that the expression of hepatitis B virus X protein (HBx) in HCC is associated with an increased expression of membrane-type 1 matrix metalloproteinase (MT1-MMP), and matrix metalloproteinase-2(MMP-2), which correlates with a poor prognosis.
|
17187364 |
2007 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma.
|
28670372 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
AMF produced by HCC was found to induce migration of different MSCs in vitro and to enhance their MMP2 activity.
|
24736611 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
In this study, we selected 46 hepatocellular carcinoma (HCC) cases, at random, and we immunohistologically examined the expression of MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, tissue inhibitor of metalloproteinases (TIMP)-1, TIMP-2, in cancerous and non-cancerous areas using avidin-biotin-peroxidase complex method.
|
17564313 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of c-myc, Ki-67, MMP-2 and VEGF in cancer tissue is related to the recurrence of HCC after tumor resection.
|
15133868 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and -9.
|
30349190 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MMP2 may act as an oncogene and may be a potential therapeutic target in HCC.
|
31157304 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings show that CK19 and MMP-2 expression may be beneficial in predicting HCC LNM and survival.
|
21104440 |
2011 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HOXD-AS1 competitively bound to miR-130a-3p that prevented SOX4 from miRNA-mediated degradation, thus activated the expression of EZH2 and MMP2 and facilitated HCC metastasis.
|
28810927 |
2017 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also observed that HCC cell migration and upregulation of the level of MMP-2/9 and downregulation of E-cadherin induced by PGE2 were suppressed by FH535, an inhibitor of β-catenin.
|
27109804 |
2016 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study, we found that irradiation increased the invasiveness of human hepatoma HepG2 cells, and pretreatment of the cells with SU1498 (an inhibitor of vascular endothelial growth factor receptor 2, VEGFR2) and GM6001 (an inhibitor of matrix metalloproteinases 2, MMP2) demonstrated that radiation-enhanced invasiveness is associated with the interplay between MMP2 and VEGF signaling.
|
24059678 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis.
|
9075667 |
1997 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our results link two drivers of invasion and metastasis in HCC and identify a novel pathway for MMP2 control.
|
25251472 |
2014 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to investigate the expression of PRL-3 in hepatocellular carcinoma (HCC) tumor tissues and determine its correlations with matrix metalloproteinases (MMP-2, MMP-9) and E-cadherin in HCC.
|
18636172 |
2008 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of Lcn2 in HCC cells significantly inhibited the growth of HCC cells in vitro and in vivo, reduced the invasive potential of cells, and inhibited the expression of matrix metalloproteinase 2 (MMP-2).
|
21132267 |
2011 |